The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant
Inge M M Lakeman,Alexandra J van den Broek,Juliën A M Vos,Daniel R Barnes,Julian Adlard,Irene L Andrulis,Adalgeir Arason,Norbert Arnold,Banu K Arun,Judith Balmaña,Daniel Barrowdale,Javier Benitez,Ake Borg,Trinidad Caldés,Maria A Caligo,Wendy K Chung,Kathleen B M Claes,GEMO Study Collaborators,EMBRACE Collaborators,J Margriet Collée,Fergus J Couch,Mary B Daly,Joe Dennis,Mallika Dhawan,Susan M Domchek,Ros Eeles,Christoph Engel,D Gareth Evans,Lidia Feliubadaló,Lenka Foretova,Eitan Friedman,Debra Frost,Patricia A Ganz,Judy Garber,Simon A Gayther,Anne-Marie Gerdes,Andrew K Godwin,David E Goldgar,Eric Hahnen,Christopher R Hake,Ute Hamann,Frans B L Hogervorst,Maartje J Hooning,John L Hopper,Peter J Hulick,Evgeny N Imyanitov,OCGN Investigators,HEBON Investigators,KconFab Investigators,Claudine Isaacs,Louise Izatt,Anna Jakubowska,Paul A James,Ramunas Janavicius,Uffe Birk Jensen,Yue Jiao,Esther M John,Vijai Joseph,Beth Y Karlan,Carolien M Kets,Irene Konstantopoulou,Ava Kwong,Clémentine Legrand,Goska Leslie,Fabienne Lesueur,Jennifer T Loud,Jan Lubiński,Siranoush Manoukian,Lesley McGuffog,Austin Miller,Denise Molina Gomes,Marco Montagna,Emmanuelle Mouret-Fourme,Katherine L Nathanson,Susan L Neuhausen,Heli Nevanlinna,Joanne Ngeow Yuen Yie,Edith Olah,Olufunmilayo I Olopade,Sue K Park,Michael T Parsons,Paolo Peterlongo,Marion Piedmonte,Paolo Radice,Johanna Rantala,Gad Rennert,Harvey A Risch,Rita K Schmutzler,Priyanka Sharma,Jacques Simard,Christian F Singer,Zsofia Stadler,Dominique Stoppa-Lyonnet,Christian Sutter,Yen Yen Tan,Manuel R Teixeira,Soo Hwang Teo,Alex Teulé,Mads Thomassen,Darcy L Thull,Marc Tischkowitz,Amanda E Toland,Nadine Tung,Elizabeth J van Rensburg,Ana Vega,Barbara Wappenschmidt,Peter Devilee,Christi J van Asperen,Jonine L Bernstein,Kenneth Offit,Douglas F Easton,Matti A Rookus,Georgia Chenevix-Trench,Antonis C Antoniou,Mark Robson,Marjanka K Schmidt,Emmanuelle Barouk-Simonet,Muriel Belotti,Pascaline Berthet,Yves-Jean Bignon,Valérie Bonadona,Brigitte Bressac-de Paillerets,Bruno Buecher,Sandrine Caputo,Olivier Caron,Laurent Castera,Virginie Caux-Moncoutier,Chrystelle Colas,Marie-Agnès Collonge-Rame,Isabelle Coupier,Antoine de Pauw,Capucine Delnatte,Camille Elan,Laurence Faivre,Sandra Fert Ferrer,Marion Gauthier-Villars,Paul Gesta,Sophie Giraud,Lisa Golmard,Claude Houdayer,Christine Lasset,Maïté Laurent,Dominique Leroux,Michel Longy,Véronique Mari,Sylvie Mazoyer,Noura Mebirouk,Isabelle Mortemousque,Fabienne Prieur,Pascal Pujol,Claire Saule,Helene Schuster,Nicolas Sevenet,Hagay Sobol,Johanna Sokolowska,Laurence Venat-Bouvet,Munaza Ahmed,Julian Barwell,Angela Brady,Paul Brennan,Carole Brewer,Jackie Cook,Rosemarie Davidson,Alan Donaldson,Alison M Dunning,Jacqueline Eason,Diana M Eccles,Helen Gregory,Helen Hanson,Patricia A Harrington,Alex Henderson,Shirley Hodgson,M John Kennedy,Fiona Lalloo,Clare Miller,Patrick J Morrison,Kai-Ren Ong,Aoife O'Shaughnessy-Kirwan,Jo Perkins,Mary E Porteous,Mark T Rogers,Lucy E Side,Katie Snape,Lisa Walker,Gord Glendon,Anna Marie Mulligan,Cora M Aalfs,Muriel A Adank,Margreet G E M Ausems,Marinus J Blok,Encarna B Gómez Garcia,Bernadette A M Heemskerk-Gerritsen,Antoinette Hollestelle,Agnes Jager,Linetta B Koppert,Marco Koudijs,Mieke Kriege,Hanne E J Meijers-Heijboer,Arjen R Mensenkamp,Thea M Mooij,Jan C Oosterwijk,Ans M W van den Ouweland,Frederieke H van der Baan,Annemieke H van der Hout,Lizet E van der Kolk,Rob B van der Luijt,Carolien H M van Deurzen,Helena C van Doorn,Klaartje van Engelen,Liselotte P van Hest,Theo A M van Os,Senno Verhoef,Maartje J Vogel,Juul T Wijnen,Jonathan Beesley,Stephen Fox,Helene Holland,Kelly-Anne Phillips,Amanda B Spurdle
DOI: https://doi.org/10.1038/s41436-021-01198-7
Abstract:Purpose: To evaluate the association between a previously published 313 variant-based breast cancer (BC) polygenic risk score (PRS313) and contralateral breast cancer (CBC) risk, in BRCA1 and BRCA2 pathogenic variant heterozygotes. Methods: We included women of European ancestry with a prevalent first primary invasive BC (BRCA1 = 6,591 with 1,402 prevalent CBC cases; BRCA2 = 4,208 with 647 prevalent CBC cases) from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), a large international retrospective series. Cox regression analysis was performed to assess the association between overall and ER-specific PRS313 and CBC risk. Results: For BRCA1 heterozygotes the estrogen receptor (ER)-negative PRS313 showed the largest association with CBC risk, hazard ratio (HR) per SD = 1.12, 95% confidence interval (CI) (1.06-1.18), C-index = 0.53; for BRCA2 heterozygotes, this was the ER-positive PRS313, HR = 1.15, 95% CI (1.07-1.25), C-index = 0.57. Adjusting for family history, age at diagnosis, treatment, or pathological characteristics for the first BC did not change association effect sizes. For women developing first BC < age 40 years, the cumulative PRS313 5th and 95th percentile 10-year CBC risks were 22% and 32% for BRCA1 and 13% and 23% for BRCA2 heterozygotes, respectively. Conclusion: The PRS313 can be used to refine individual CBC risks for BRCA1/2 heterozygotes of European ancestry, however the PRS313 needs to be considered in the context of a multifactorial risk model to evaluate whether it might influence clinical decision-making.